Pharmacy Considerations

Conventional Treatment Strategies
Insure Strategies
Leading the Way

Surfactant utilization

When evaluating surfactants, consider the impact of cumulative volume, need for redosing, and product wastage on the total cost of surfactant therapy.

With a low volume and high rates of single-dose success, CUROSURF® (poractant alfa) may help minimize waste and reduce surfactant utilization in your NICU.1-11

CUROSURF® (poractant alfa) delivers more surfactant with less volume

More surfactant, less volume*1-6

Initial and repeat doses of CUROSURF® (poractant alfa) are delivered at a lower volume vs other exogenous surfactants.1-6

CUROSURF delivers more than twice the phospholipid concentration (mg/mL) of other exogenous surfactants.1-6

More surfactant, less volume

*Based on a 1000-g infant and manufacturer’s dosing schedule.
While both CUROSURF and Surfaxin are approved for neonatal RDS, CUROSURF is approved for treatment and Surfaxin is approved for prophylaxis. See labeled indications.

  • Initial dose of CUROSURF delivers a higher concentration of surfactant at a lower volume vs other exogenous surfactants1-6
  • Less volume may improve tolerability and has the potential to reduce complications such as airway obstruction12,13
  • Clinical studies have not established that lower volume results in superior efficacy or safety based on clinically relevant end points
  • While clinical studies have demonstrated that phospholipids are an essential element, they have not established the quantity required for optimal surfactant efficacy

Initial and repeat doses of CUROSURF® (poractant alfa) are delivered at a lower volume vs other exogenous surfactants.1-6

CUROSURF delivers more than twice the phospholipid concentration (mg/mL) of other exogenous surfactants.1-6

CUROSURF cost and benefits

Cost per mg of surfactant14

SURFACTANT VIAL SIZE SURFACTANT (mg) WAC PRICE PER VIAL* PRICE PER mg
CUROSURF® (poractant alfa) 3.0 mL 240 mg $731.48 $3.05
CUROSURF® (poractant alfa) 1.5 mL 120 mg $370.96 $3.09

*Actual contract price will vary.

CUROSURF demonstrates consistently high rates of single-dose success

Single-dose success in clinical studies7-11

Across studies, infants treated with the 200 mg/kg initial dose of CUROSURF® (poractant alfa) demonstrated higher rates of single-dose success vs those treated with Survanta® (beractant).1,3,4,6

CLINICAL STUDY N* GESTATIONAL AGE CUROSURF (200 mg/kg)
SINGLE-DOSE SUCCESS
Dizdar EA, et al. 20117 106 Median 28 wks 88%
Sandri F, et al. 2010 (treatment arm)8 103 Mean 27.0 ± 1.0 wks 78%
Dani C, et al. 20049 27 <30 wks 74%
Ramanathan R, et al. 200410 293 Mean 28.7 ± 2.0 wks 73%
Verder H, et al. 199911 60 25-29 wks 88%

*Total number of infants randomized.
Single-dose success is defined as no need for repeat doses of CUROSURF® (poractant alfa).

  • High rates of single-dose success limit the need to open additional vials for repeat dosing7-11
  • Clinical studies have not established that fewer doses result in superior efficacy or safety based on clinically relevant end points

Across studies, infants treated with the 200 mg/kg initial dose of CUROSURF® (poractant alfa) demonstrated higher rates of single-dose success vs those treated with Survanta® (beractant).1,3,4,6

CUROSURF may help minimize wastage

Infants’ administration experience15

CUROSURF is a thin suspension that demonstrates a low reflux rate and fast recovery time after administration.1,10

1st DOSE VOLUME1 % INITIAL DOSES ADMINISTERED IN
UNDER FIVE MIN
REFLUX RATE 5—15 MIN AFTER ADMINISTRATION RECOVERY TIME AFTER ADMINISTRATION
2.5 mL/kg 58.9% 3.5% 81% of babies
recovered within 1 minute

Adapted from Gerdes JS, et al. J Pediatr Pharmacol Ther. 2006.

  • In an open-label, observational study, the low rate of reflux may have been attributed to small volumes and low viscosity15
  • Low rates of reflux may help minimize drug loss, resource utilization, and the need to open multiple vials15

CUROSURF is a thin suspension that demonstrates a low reflux rate and fast recovery time after administration.1,10